Small-molecule ghrelin mimetic · Fact sheet

Ibutamoren

Also known as MK-677 · MK-0677 · Ibutamoren mesylate

Ibutamoren, often called MK-677, is a small molecule rather than a peptide or SARM. It increased growth hormone and lean mass in older adults, but did not improve strength or function in that trial and remains unapproved.

Not FDA approvedEarly human evidence

What is Ibutamoren?

Ibutamoren acts through the ghrelin receptor and stimulates the growth-hormone/IGF-1 pathway. A change in lean mass includes more than new functional muscle.

Benefits & claims

People look for greater appetite, muscle growth, recovery, sleep, and anti-aging effects. The human findings are more limited than this collection of claims.

What the evidence supports

  • The older-adult trial found increases in growth hormone, IGF-1, and fat-free mass.
  • It did not demonstrate better strength or physical function; hip-fracture findings were also unfavorable overall.
Research areas
  • Age-related body composition
  • Growth hormone and IGF-1
  • Recovery after hip fracture

Dosage & frequency

Human study context

A human trial tested oral ibutamoren in older adults. Increased GH, IGF-1 or lean mass does not establish improved strength, function, or safe anti-aging use.

Randomized older-adult trial

65 healthy adults age 60–81

Amount
25 mg
Frequency
Once daily in a two-year study
Route studied or labeled
Oral

Lean-mass and hormone findings did not establish improved strength or function.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Ibutamoren/MK-677 is a small-molecule ghrelin-receptor agonist, not a peptide.

Interactions & precautions

  • The older-adult trial does not establish safety with other GH-directed treatments or diabetes medicines; changes in glucose handling matter to this evidence gap.

What is still unresolved

  • A favorable long-term benefit–risk balance and clinically useful treatment population remain unestablished.

Side effects & risks

  • Increased appetite, edema, muscle discomfort, higher fasting glucose, and reduced insulin sensitivity were reported in the older-adult trial.
  • A hip-fracture trial was stopped for a congestive-heart-failure signal; risk may depend on the population.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

A randomized study in 65 older adults found more fat-free mass without corresponding strength or function gains. A separate hip-fracture study was stopped early after a heart-failure safety signal.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Better sleep alongside strong hunger

An author described better sleep and unusually strong hunger during their first three days with MK-677 while also using tirzepatide. Later hunger became easier to manage after tirzepatide changed.

Reported use in this account

Product
Product described as MK-677
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Three days at the initial report

Other exposures described: Tirzepatide; its schedule changed during the discussion

Concurrent tirzepatide prevents isolating the effects. The author explicitly said it was too early to assess muscle-related claims.

Read the original account
Mixed account · personal report

No added hunger, with possible better sleep

The original poster described no added hunger and little change apart from possible better sleep during MK-677 use.

Reported use in this account

Product
Product described as MK-677
Amount
10 mg
Frequency
Daily
Route
Not specified clearly
Duration
Not specified clearly

Other exposures described: Earlier RAD140 exposure, not described as concurrent

Despite the forum name, ibutamoren is not a SARM. Previous other-drug exposure, unverified products and subjective outcomes limit interpretation; this account does not establish muscle gain.

Read the original MK-677 account
Mixed account · personal report

Perceived recovery with intolerable hunger and fatigue

A different commenter described easier recovery between workouts, but hunger cramps, lethargy and fluid retention that they found intolerable during solo MK-677 use.

Reported use in this account

Product
Product described as MK-677
Amount
10 mg
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Not specified clearly

This is a separate person's experience from the original post. Frequency, product identity and measured outcomes are unverified; subjective recovery does not establish muscle gain.

Read the separate commenter's account

Approval status

Ibutamoren has no FDA-approved product. Historical trials in older adults do not establish approval for bodybuilding, recovery, or anti-aging.

No FDA-approved product

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether body-composition changes improve long-term function
  • Long-term cardiovascular and glucose effects
  • Benefits and harms in younger performance-oriented users

Summary

MK-677 can change hormones and body composition, but the trials do not support equating those changes with better performance or healthy aging.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety concerns for selected bulk substances

    Ingredient-specific safety findings; compounding review is not drug approval.

  2. pubmedIbutamoren in healthy older adults

    Randomized study in 65 adults; lean-mass increase without strength or functional improvement.

  3. pubmedIbutamoren after hip fracture

    123-participant Phase IIb study terminated early after a heart-failure signal.

How we assess sources · Suggest a correction